Legend Biotech (NASDAQ:LEGN – Get Free Report) was upgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a note issued to investors on Saturday, Wall Street Zen reports.
A number of other research firms have also issued reports on LEGN. Barclays dropped their target price on shares of Legend Biotech from $68.00 to $61.00 and set an “overweight” rating for the company in a report on Wednesday, November 11th. Raymond James Financial reissued an “outperform” rating and issued a $58.00 price target on shares of Legend Biotech in a research note on Monday, July 27th. Morgan Stanley lowered their price target on shares of Legend Biotech from $49.00 to $43.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 11th. Weiss Ratings raised shares of Legend Biotech from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, November 9th. Finally, TD Cowen dropped their price objective on shares of Legend Biotech from $29.00 to $24.00 and set a “hold” rating for the company in a research note on Wednesday, August 12th. Nine research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $50.85.
Read Our Latest Research Report on LEGN
Legend Biotech Price Performance
Shares of NASDAQ:LEGN opened at $17.50 on Friday. The business’s 50 day moving average price is $19.57 and its 200-day moving average price is $22.12. The firm has a market capitalization of $3.39 billion, a PE ratio of -1,748.25 and a beta of 0.55. Legend Biotech has a 1 year low of $16.24 and a 1 year high of $37.50.
Legend Biotech (NASDAQ:LEGN – Get Free Report) last issued its quarterly earnings results on Tuesday, November 10th. The company reported $0.14 EPS for the quarter, topping the consensus estimate of $0.01 by $0.13. The firm had revenue of $359.50 million during the quarter, compared to analysts’ expectations of $361.46 million. Legend Biotech had a negative return on equity of 0.03% and a negative net margin of 0.02%. The firm’s revenue for the quarter was up 32.0% on a year-over-year basis. During the same period in the previous year, the business earned ($0.05) earnings per share. As a group, analysts expect that Legend Biotech will post -0.02 earnings per share for the current year.
Insider Buying and Selling
In related news, Director Corazon (Corsee) D. Sanders sold 27,370 shares of the company’s stock in a transaction that occurred on Tuesday, September 29th. The stock was sold at an average price of $9.46, for a total value of $258,920.20. Following the transaction, the director directly owned 52,731 shares in the company, valued at approximately $498,835.26. This represents a 34.17% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Carlos E. Santos sold 5,430 shares of the company’s stock in a transaction that occurred on Monday, September 21st. The shares were sold at an average price of $9.14, for a total value of $49,630.20. Following the completion of the transaction, the chief financial officer owned 14,246 shares in the company, valued at $130,208.44. This represents a 27.60% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.02% of the stock is owned by company insiders.
Institutional Investors Weigh In On Legend Biotech
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Assenagon Asset Management S.A. acquired a new position in shares of Legend Biotech in the 2nd quarter valued at $55,307,000. Squarepoint Ops LLC grew its holdings in shares of Legend Biotech by 60.4% during the 2nd quarter. Squarepoint Ops LLC now owns 769,252 shares of the company’s stock worth $22,216,000 after purchasing an additional 289,772 shares during the period. Renaissance Technologies LLC increased its position in shares of Legend Biotech by 29.5% during the 1st quarter. Renaissance Technologies LLC now owns 521,800 shares of the company’s stock worth $9,439,000 after purchasing an additional 119,000 shares during the last quarter. Arrowstreet Capital Limited Partnership increased its position in shares of Legend Biotech by 343.6% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 406,901 shares of the company’s stock worth $7,361,000 after purchasing an additional 315,176 shares during the last quarter. Finally, Tidal Investments LLC increased its position in shares of Legend Biotech by 34.0% during the 2nd quarter. Tidal Investments LLC now owns 240,476 shares of the company’s stock worth $6,945,000 after purchasing an additional 61,023 shares during the last quarter. Institutional investors and hedge funds own 70.89% of the company’s stock.
Legend Biotech Company Profile
Legend Biotech is a biotechnology company focused on developing cell therapies for cancer, with an emphasis on chimeric antigen receptor (CAR) T-cell treatments. Founded in 2014, the company is headquartered in Somerset, New Jersey, and conducts research and development activities in the United States and China. Its lead product is CARVYKTI (ciltacabtagene autoleucel), a BCMA-directed CAR-T therapy for certain adults with relapsed or refractory multiple myeloma. Legend developed the therapy with Janssen, now part of Johnson & Johnson’s Innovative Medicine business, which collaborates on its commercialization.
Further Reading
- Five stocks we like better than Legend Biotech
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Legend Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Legend Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
